Results 191 to 200 of about 2,458,151 (310)

Intensive Care Unit [PDF]

open access: yes, 2017
吉岡 伊作   +3 more
core   +1 more source

Multidimensional Profiling of MRI‐Negative Temporal Lobe Epilepsy Uncovers Distinct Phenotypes

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Although hippocampal sclerosis (TLE‐HS) represents the most frequent cause of temporal lobe epilepsy (TLE), up to 30% of patients show no lesion on visual MRI inspection (TLE‐MRIneg). These cases pose diagnostic and therapeutic challenges and are underrepresented in surgical series.
Alice Ballerini   +28 more
wiley   +1 more source

Necessary additional steps in ultrasound guided central venous catheter placement: getting to the heart of the matter

open access: yesCritical Care, 2017
Thei S. Steenvoorden   +3 more
doaj   +1 more source

Intensive Care Unit [PDF]

open access: yes, 2012
吉岡 伊作   +4 more
core   +1 more source

Location‐Specific Hematoma Volume Predicts Early Neurological Deterioration in Supratentorial ICH

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Early neurological deterioration (END) adversely affects outcomes in patients with intracerebral hemorrhage (ICH). This study aimed to determine the location‐specific hematoma volumes for END in supratentorial ICH patients. Methods We retrospectively analyzed supratentorial ICH patients presenting from two prospective cohorts.
Zuoqiao Li   +10 more
wiley   +1 more source

National cost of intensive care in Japan from 2018 to 2022. [PDF]

open access: yesJ Intensive Care
Ohbe H   +13 more
europepmc   +1 more source

Intensive Care Unit [PDF]

open access: yes, 2006
丹下 大祐   +3 more
core   +1 more source

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz   +9 more
wiley   +1 more source

Intensive Care Unit [PDF]

open access: yes, 2004
土居 寿男   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy